This medication is used for treating metastatic bone damages in breast cancer (tumor development away from primary site), pathological hypercalcemia (increased calcium levels due to disease) in bone tumors, and in post-menopausal osteoporosis to minimize the risk of fractures.

This medicine is used orally or intravenously. The injectable form is injected into a vein by a medical professional. However, if you are self-injecting or doing it at home, ensure that you follow the correct procedure and all relevant precautions. The dose is dependent on the age, condition and its severity. The lowest oral dose should be used for the elderly. This medicine is not recommended for children.

Please store the oral form of this medicine at room temperature (18-25 Celsius). Please keep away from excessive light, moisture, and children. Please read the leaflet provided with the medicine for further storage guidance.

The patients administered with this medicine may experience rise in body temperature, flu-like-syndrome, hypocalcemia (low calcium levels), headache, myalgia (muscular pain), and gastrointestinal disturbances.

The patients with severe hepatic (liver) disease, bone function and mineral disturbances, risk of osteonecrosis (bone death due to decreased blood supply) of the jaw and femoral bone fracture should be cautious. Please monitor renal (kidney) function, and levels of calcium, phosphate and magnesium during use of this medicine. Please advise patients to report ear, thigh, hip and groin pain.

This medicine is not recommended for pregnant females. This medicine is not recommended for nursing females.

The patients with Hypocalcemia (decreased calcium levels) and allergic reactions (especially in children) to Ibandronic Acid and bisphosphonates should avoid use of this medicine.